AEterna Zentaris Inc. (USA) (NASDAQ:AEZS) announced it has reached its goal of recruiting 500 patients for its pivotal Phase 3 ZoptEC (Zoptarelin Doxorubicin in Endometrial Cancer) clinical study with zoptarelin doxorubicin in women with advanced, recurrent or metastatic endometrial cancer. The trial is being conducted in over 120 sites in North America, Europe and Israel. The primary efficacy endpoint is improvement in overall survival.
Following its first pre‑specified interim analysis last April, a Data and Safety Monitoring Board recommended that the ZoptEC Phase 3 study continue as planned. A second interim analysis is expected during Q4, 2015 at approximately 192 events, with the final analysis planned at an anticipated 384 events. The trial is expected to be completed by the end of 2016.
David A. Dodd, Chairman and CEO of Aeterna Zentaris, commented, “We are very excited to have completed patient recruitment for our ZoptEC Phase 3 trial in endometrial cancer earlier than expected, and I would like to thank everyone involved in this project for their steadfast commitment. We believe zoptarelin doxorubicin has the potential to become the first FDA approved medical therapy for advanced, recurrent endometrial cancer. This could result in its rapid adoption as a novel core therapy for patient treatment and management, and therefore, could represent a significant market opportunity for the Company. Moving forward, we are continuing to develop our commercialization plans regarding zoptarelin doxorubicin in this indication, including establishing additional partnerships in territories that we do not intend to pursue ourselves. Furthermore, contingent on the success of the ZoptEC program, we have additional areas of interest for further therapeutic development, including ovarian, prostate and triple negative breast cancer. Our commitment is to provide therapies to patients and their physicians that can potentially improve and extend the quality of lives.” (Original Source)
Shares of Aeterna Zentaris closed yesterday at $0.27 . AEZS has a 1-year high of $1.54 and a 1-year low of $0.26. The stock’s 50-day moving average is $0.31 and its 200-day moving average is $0.51.
On the ratings front, Aeterna Zentaris has been the subject of a number of recent research reports. In a report issued on June 15, Maxim Group analyst Jason Kolbert maintained a Buy rating on AEZS, with a price target of $2, which implies an upside of 640.7% from current levels. Separately, on May 21, H.C. Wainwright’s Swayampakula Ramakanth reiterated a Buy rating on the stock and has a price target of $1.25.
According to TipRanks.com, which ranks over 7,500 financial analysts and bloggers to gauge the performance of their past recommendations, Jason Kolbert and Swayampakula Ramakanth have a total average return of -0.3% and 7.2% respectively. Kolbert has a success rate of 39.9% and is ranked #2870 out of 3684 analysts, while Ramakanth has a success rate of 43.9% and is ranked #1137.
AEterna Zentaris Inc is a specialty biopharmaceutical company engaged in developing novel treatments in oncology, endocrinologyand women’s health.